MedTrace Logo

Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial

NCT00110448 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2539

Last updated 2016-11-02

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan.

Conditions

  • Coronary Disease
  • Arteriosclerosis
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Aspirin

Aspirin 81 mg or 100 mg per day

DRUG

No aspirin

No aspirin use

Sponsors & Collaborators

  • Kumamoto University

    lead OTHER

Principal Investigators

  • Hisao Ogawa, MD · Professor of Medicine, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

  • Yoshihiko Saito, MD · Professor of Medicine, First Department of Internal Medicine, Nara Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00110448 on ClinicalTrials.gov